文献速递临床试验与 GCP流行病学与生物统计

急性心肌梗死完全血运重建与仅罪犯病变血运重建对比(完全血运重建试验协作组):随机试验的个体患者数据荟萃分析

Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials.
PubMed 文献 · Lancet · 2025-11-09

该个体患者数据荟萃分析纳入6项随机对照试验共8836例急性心肌梗死合并多支冠状动脉病变患者,比较完全血运重建策略与仅罪犯病变PCI策略。中位随访36.0个月,完全血运重建组心血管死亡或新发心肌梗死风险低于仅罪犯病变组(HR 0.76,95%CI 0.67-0.87,p<0.0001),心血管死亡(HR 0.76,95%CI 0.62-0.93,p=0.0091)及全因死亡(HR 0.85,95%CI 0.73-0.99,p=0.039)亦较低。

要点

  • 完全血运重建组心血管死亡或新发心肌梗死发生率为9.0%,仅罪犯病变组为11.5%。
  • 完全血运重建组心血管死亡发生率为3.6%,仅罪犯病变组为4.6%。
  • 完全血运重建组全因死亡发生率为7.2%,仅罪犯病变组为8.1%。

核心结论

  • 在急性心肌梗死合并多支冠状动脉病变患者中,与仅罪犯病变PCI策略相比,完全血运重建降低了心血管死亡或新发心肌梗死的复合终点以及心血管死亡,全因死亡亦较低。

研究设计与样本

  • 本研究为个体患者数据荟萃分析,纳入至少250例患者、比较完全血运重建策略(PCI)与仅罪犯病变PCI策略的随机对照试验,纳入急性ST段抬高型心肌梗死或非ST段抬高型心肌梗死患者。
  • 检索Ovid MEDLINE、Embase和Cochrane对照试验中心注册库(CENTRAL),检索1996年至2025年9月15日发表的随机对照试验。
  • 共纳入6项随机对照试验,涉及8836例患者,中位年龄65.8岁(IQR 57.0-76.0),女性2088例(23.6%),男性6748例(76.4%)。
  • 7768例(87.9%)患者表现为ST段抬高型心肌梗死,1068例(12.1%)表现为非ST段抬高型心肌梗死。
  • 采用一阶段个体患者数据荟萃分析,使用Cox frailty模型;主要终点为心血管死亡或新发心肌梗死的复合终点及心血管死亡;基于预设α水平0.04,在心血管死亡或新发心肌梗死降低的前提下对心血管死亡进行层次检验。

主要发现

  • 中位随访36.0个月(IQR 30.6-48.0),完全血运重建组4259例患者中382例(9.0%)发生心血管死亡或新发心肌梗死,仅罪犯病变组4577例中528例(11.5%)发生(HR 0.76,95%CI 0.67-0.87,p<0.0001)。
  • 完全血运重建组心血管死亡155例(3.6%),仅罪犯病变组209例(4.6%)(HR 0.76,95%CI 0.62-0.93,p=0.0091)。
  • 完全血运重建组全因死亡308例(7.2%),仅罪犯病变组370例(8.1%)(HR 0.85,95%CI 0.73-0.99,p=0.039)。
  • 非心血管死亡两组相似:完全血运重建组153例(3.6%)vs 仅罪犯病变组161例(3.5%)(HR 0.98,95%CI 0.78-1.22,p=0.85)。
  • 完全血运重建组新发心肌梗死255例(6.0%),仅罪犯病变组357例(7.8%)(HR 0.76,95%CI 0.65-0.90,p=0.0011)。

临床怎么用

  • 作者指出,这些数据提供了迄今最强、最稳健的证据,表明完全血运重建改善重要心血管临床结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients presenting with acute coronary syndromes and multivessel coronary artery disease, the question of whether to undertake a strategy of complete revascularisation in cases in which percutaneous coronary intervention (PCI) is performed routinely on non-culprit lesions (in addition to the culprit lesion) or whether to restrict PCI only to the culprit lesion is a common dilemma. The Complete Revascularisation Trialists' Collaboration aimed to determine, based on the totality of data from randomised trials, the effect of a complete revascularisation strategy on major cardiovascular events and whether it reduces cardiovascular death. METHODS: In this individual patient data meta-analysis, trials were included if they enrolled at least 250 patients, compared a complete revascularisation strategy (with PCI) to a culprit lesion-only PCI strategy, and enrolled patients presenting with acute ST-segment elevation myocardial infarction or non-ST-segment elevation myocardial infarction. To ensure that no trials were overlooked, we searched Ovid MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) for randomised controlled trials published between 1996 and Sept 15, 2025. The primary outcomes were the composite of cardiovascular death or new myocardial infarction and cardiovascular death alone. Hierarchical testing of cardiovascular death alone was planned contingent on reduction in cardiovascular death or new myocardial infarction based on the prespecified alpha level of 0·04. A one-stage individual patient data meta-analysis was performed using a Cox frailty model. All-cause death was the secondary outcome; non-cardiovascular death and new myocardial infarction were additional outcomes. All analyses included all randomly assigned patients. The meta-analysis was registered in PROSPERO, CRD420251124098. FINDINGS: Six randomised controlled trials involving 8836 individuals were included. The median age was 65·8 years (IQR 57·0-76·0), and 2088 (23·6%) patients were female and 6748 (76·4%) were male. Overall, 7768 (87·9%) patients presented with ST-segment elevation myocardial infarction and 1068 (12·1%) with non-ST-segment elevation myocardial infarction. At a median follow-up of 36·0 months (IQR 30·6-48·0), cardiovascular death or new myocardial infarction occurred in 382 (9·0%) of 4259 patients in the complete revascularisation group compared with 528 (11·5%) of 4577 patients in the culprit lesion-only group (hazard ratio [HR] 0·76 [95% CI 0·67-0·87], p<0·0001). There were 155 (3·6%) cardiovascular deaths in the complete revascularisation group compared with 209 (4·6%) in the culprit lesion-only group (HR 0·76 [95% CI 0·62-0·93], p=0·0091). All-cause death occurred in 308 (7·2%) patients in the complete revascularisation group compared with 370 (8·1%) patients in the culprit lesion-only group (HR 0·85 [95% CI 0·73-0·99], p=0·039). Non-cardiovascular death was similar between the groups (153 [3·6%] in the complete revascularisation group vs 161 [3·5%] in the culprit lesion-only group; HR 0·98 [95% CI 0·78-1·22], p=0·85). Complete revascularisation reduced new myocardial infarctions compared with culprit lesion-only PCI (255 [6·0%] vs 357 [7·8%]; HR 0·76 [95% CI 0·65-0·90], p=0·0011). INTERPRETATION: In patients presenting with acute myocardial infarction and multivessel disease, complete revascularisation reduced the composite of cardiovascular death or new myocardial infarction as well as cardiovascular death alone compared with a culprit lesion-only PCI strategy. In addition, all-cause death was lower with complete revascularisation. These data provide the strongest and most robust evidence to date that complete revascularisation improves important cardiovascular clinical outcomes. FUNDING: None.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Mehta SR, Tiong DTW, Böhm F, et al. Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials. Lancet. 2025. PMID: 41223860. doi:10.1016/S0140-6736(25)02170-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。